Insights

CSL (ASX:CSL) earnings release. How does it compare to expectations?

Here’s how the CSL result compares to what the market was expecting…
The post CSL (ASX:CSL) earnings release. How does it compare to expectations? appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) share price is trading lower on Wednesday following the release of its full year results.

In afternoon trade, the biotherapeutics company’s shares are down 1% to $295.35.

How did CSL perform in FY 2021?

For the 12 months ended 30 June, CSL reported a 9.6% in constant currency revenue to US$10,026 million.

This was driven by a 6% increase in CSL Behring revenue and a 30% increase in revenue from its influenza vaccines business, Seqirus. This reflects strong demand for its immunoglobulin portfolio and record demand for seasonal influenza vaccines.

On the bottom line, CSL reported net profit after tax growth of 10% to US$2,307 million. This compares favourably to its guidance of 3% to 8% growth in FY 2021.

However, that wasn’t enough to keep the CSL share price from dropping today. Investors have been selling its shares after management warned that its FY 2022 profits would decline by 2.5% to 6.8% on its constant currency result or 5% to 9% on its reported result.

How does this compare to expectations?

Analysts at Goldman Sachs have been looking over the result and have given their feedback.

The broker said: “FY21 modestly ahead of expectations (revenue/EBIT/NPAT +2%/-1%/+2% vs. VA consensus). CSL delivered +10% revenue and +10% earnings growth in a year of widely understood challenges. In the core Behring division, revenues grew +6% (vs. cons +5%), with the entirety of the beat driven by IG.”

“Seqirus held up reasonably well after a stellar 1H, although ultimately missed consensus EBIT expectations by -7% despite a modest +1% beat on sales,” it added.

As mentioned above, the main drag on the CSL share price appears to be its guidance. Goldman Sachs notes that constant currency net profit after tax of US$2,150 million to US$2,250 million falls short of the analyst consensus estimate of US$2,289 million by 6% to 2%.

And while it acknowledges that management is often conservative with its guidance, these are unprecedented times.

Goldman said: “FY22 net profit is guided to $2,150m-2,250m (vs. FY21 level of $2,375m) on sales guidance of +2-5% (both in constant currency). CSL has stated that FY22 will be a ‘transitional year’ and, despite ‘robust demand’, guides to further margin pressure, primarily due to increased plasma costs. Whilst management has a long-standing reputation for conservative guidance, the current conditions are clearly unprecedented.”

The post CSL (ASX:CSL) earnings release. How does it compare to expectations? appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

CSL (ASX:CSL) share price slumps despite 10% revenue growth
CSL (ASX:CSL) dividend boosted 10%. Shares slide regardless
ASX 200 midday update: BHP sinks, CSL outperforms guidance, Coles rises

CSL (ASX:CSL) share price in focus after outperforming FY21 guidance
5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!